<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期间（包括这两个日期）购买 Jasper Therapeutics, Inc.（纳斯达克：JSPR）证券的投资者提起集体诉讼。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 11 月 18 日之前向法院提出申请。</p>
<p>那么：如果您在集体诉讼期间购买了 Jasper Therapeutics 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Jasper Therapeutics 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 11 月 18 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的律师事务所没有相应的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一的律师事务所。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，被告作出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）Jasper 缺乏必要的控制和程序，以确保其依赖的第三方制造商按照 cGMP 法规完全制造产品，并且在临床试验中适用；（2）上述失误增加了正在进行的研究结果混淆的风险，从而对 Jasper 产品的监管和商业前景产生负面影响，包括 briquilimab；（3）上述失误增加了采取破坏性成本削减措施的可能性；（4）因此，Jasper 的业务和/或财务前景，以及 briquilimab 的临床和/或商业前景被夸大；（5）因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Jasper Therapeutics 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者在任何潜在未来赔偿中的分享能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约， NY 10016</p>
<p>电话: (212) 686-1060</p>
<p>免费电话: (866) 767-3653</p>
<p>传真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0"/></p>

JSPR

<p>罗森律师事务所已代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期间购买了 Jasper Therapeutics, Inc.（纳斯达克代码：JSPR）证券的投资者提起集体诉讼。投资者可能有权获得赔偿，无需预付费用。诉讼指控 Jasper 在其制造控制和产品前景方面做出了虚假陈述，导致投资者遭受损失。感兴趣的方可以在 2025 年 11 月 18 日之前联系该事务所加入集体诉讼</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期间（包括这两个日期）购买 Jasper Therapeutics, Inc.（纳斯达克：JSPR）证券的投资者提起集体诉讼。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 11 月 18 日之前向法院提出申请。</p>
</div><p>So What: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您在集体诉讼期间购买了 Jasper Therapeutics 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Jasper Therapeutics 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 11 月 18 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的律师事务所没有相应的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一的律师事务所。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，被告作出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）Jasper 缺乏必要的控制和程序，以确保其依赖的第三方制造商按照 cGMP 法规完全制造产品，并且在临床试验中适用；（2）上述失误增加了正在进行的研究结果混淆的风险，从而对 Jasper 产品的监管和商业前景产生负面影响，包括 briquilimab；（3）上述失误增加了采取破坏性成本削减措施的可能性；（4）因此，Jasper 的业务和/或财务前景，以及 briquilimab 的临床和/或商业前景被夸大；（5）因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Jasper Therapeutics 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者在任何潜在未来赔偿中的分享能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC84724&amp;Transmission_Id=202509271036PR_NEWS_USPR_____DC84724&amp;DateId=20250927"/></p>

JSPR 投资者有机会主导 Jasper Therapeutics, Inc.的证券欺诈诉讼